{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:33Z","timestamp":1790797053726,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11102-025-01548-7","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:11:40Z","timestamp":1750587100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia"],"prefix":"10.1007","volume":"28","author":[{"given":"Angelo","family":"Milioto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Petolicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cocchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"issue":"6","key":"1548_CR1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s11154-024-09915-8","volume":"25","author":"F Chasseloup","year":"2024","unstructured":"Chasseloup F, Bernard V, Chanson P (2024) Prolactin: structure, receptors, and functions. Rev Endocr Metab Disord 25(6):953\u2013966. https:\/\/doi.org\/10.1007\/s11154-024-09915-8","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"1548_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1548_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2265.1982.tb03159.x","volume":"16","author":"PJ Moult","year":"1982","unstructured":"Moult PJ, Rees LH, Besser GM (1982) Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea an the response to Bromocriptine therapy. Clin Endocrinol (Oxf) 16(2):153\u2013162. https:\/\/doi.org\/10.1111\/j.1365-2265.1982.tb03159.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1548_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/biolre\/ioy059","volume":"99","author":"BR Zirkin","year":"2018","unstructured":"Zirkin BR, Papadopoulos V (2018) Leydig cells: formation, function, and regulation. Biol Reprod 99(1):101\u2013111. https:\/\/doi.org\/10.1093\/biolre\/ioy059","journal-title":"Biol Reprod"},{"issue":"12","key":"1548_CR5","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s40618-022-01859-7","volume":"45","author":"AM Isidori","year":"2022","unstructured":"Isidori AM, Aversa A, Calogero A, Ferlin A, Francavilla S, Lanfranco F et al (2022) Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian society of andrology and sexual medicine (SIAMS) and the Italian society of endocrinology (SIE). J Endocrinol Invest 45(12):2385\u20132403. https:\/\/doi.org\/10.1007\/s40618-022-01859-7","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1548_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A et al (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64(3):307\u2013313. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02461.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1548_CR7","doi-asserted-by":"publisher","unstructured":"Calle-Rodrigue C RD, Giannini, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT et al (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73(11):1046\u20131052. https:\/\/doi.org\/10.4065\/73.11.1046","DOI":"10.4065\/73.11.1046"},{"issue":"3","key":"1548_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3803\/EnM.2020.760","volume":"35","author":"A Al-Sharefi","year":"2020","unstructured":"Al-Sharefi A, Quinton R (2020) Current National and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab (Seoul) 35(3):526\u2013540. https:\/\/doi.org\/10.3803\/EnM.2020.760","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"1548_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000497205","volume":"109","author":"NC Olarescu","year":"2019","unstructured":"Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G et al (2019) Aggressive Malignant Prolactinomas Neuroendocrinol 109(1):57\u201369. https:\/\/doi.org\/10.1159\/000497205","journal-title":"Aggressive Malignant Prolactinomas Neuroendocrinol"},{"key":"1548_CR10","doi-asserted-by":"crossref","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. Oxford Academic, pp 273\u2013288","DOI":"10.1210\/jc.2010-1692"},{"issue":"1","key":"1548_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"11","key":"1548_CR12","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"issue":"10418","key":"1548_CR13","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","volume":"402","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M (2023) Cushing\u2019s syndrome. Lancet 402(10418):2237\u20132252. https:\/\/doi.org\/10.1016\/S0140-6736(23)01961-X","journal-title":"Lancet"},{"key":"1548_CR14","doi-asserted-by":"publisher","unstructured":"Samperi I, Lithgow K, Karavitaki N, Hyperprolactinaemia (2019) J Clin Med 8(12). https:\/\/doi.org\/10.3390\/jcm8122203","DOI":"10.3390\/jcm8122203"},{"issue":"1","key":"1548_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-019-0087-y","volume":"5","author":"A Salonia","year":"2019","unstructured":"Salonia A, Rastrelli G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA et al (2019) Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 5(1):38. https:\/\/doi.org\/10.1038\/s41572-019-0087-y","journal-title":"Nat Rev Dis Primers"},{"key":"1548_CR16","doi-asserted-by":"publisher","unstructured":"Tsametis CP, Isidori AM (2018) Testosterone replacement therapy: for whom, when and how? Metabolism. 86:69\u201378. https:\/\/doi.org\/10.1016\/j.metabol.2018.03.007","DOI":"10.1016\/j.metabol.2018.03.007"},{"issue":"6","key":"1548_CR17","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/andr.12867","volume":"8","author":"M Zitzmann","year":"2020","unstructured":"Zitzmann M (2020) Testosterone, mood, behaviour and quality of life. Andrology 8(6):1598\u20131605. https:\/\/doi.org\/10.1111\/andr.12867","journal-title":"Andrology"},{"key":"1548_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/CEOR.S285434","volume":"13","author":"S Yeo","year":"2021","unstructured":"Yeo S, Holl K, Penaherrera N, Wissinger U, Anstee K, Wyn R (2021) Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: A narrative review. Clinicoecon Outcomes Res 13:31\u201338. https:\/\/doi.org\/10.2147\/CEOR.S285434","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"1548_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","volume":"27","author":"SM Constantinescu","year":"2024","unstructured":"Constantinescu SM, Maiter D, Alexopoulou O (2024) Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists. Pituitary 27(5):625\u2013634. https:\/\/doi.org\/10.1007\/s11102-024-01445-5","journal-title":"Pituitary"},{"issue":"3","key":"1548_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Supplement1","key":"1548_CR21","doi-asserted-by":"publisher","first-page":"A632","DOI":"10.1210\/jendso\/bvab048.1289","volume":"5","author":"M Voica","year":"2021","unstructured":"Voica M, Tetlay M, Thompson DV, Hasan F (2021) Recovery of male hypogonadism following successful treatment of prolactinoma: the experience of an integrated health network. J Endocr Soc 5(Supplement1):A632\u2013A3. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1289","journal-title":"J Endocr Soc"},{"key":"1548_CR22","doi-asserted-by":"publisher","unstructured":"Guitelman MA, Cardenas G, Rogozinski A, Ballarino C, Battistone MF, Danilowicz K et al (2024) 12342 retrospective multicenter study of prolactinomas in men. J Endocr Soc 8(Supplement1). https:\/\/doi.org\/10.1210\/jendso\/bvae163.1323","DOI":"10.1210\/jendso\/bvae163.1323"},{"key":"1548_CR23","doi-asserted-by":"publisher","unstructured":"Sehemby M, Lila AR, Sarathi V, Shah R, Sankhe S, Jaiswal SK et al (2020) Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on Cabergoline. J Clin Endocrinol Metab 105(12). https:\/\/doi.org\/10.1210\/clinem\/dgaa650","DOI":"10.1210\/clinem\/dgaa650"},{"issue":"4","key":"1548_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11102-022-01242-y","volume":"25","author":"KM Al Dahmani","year":"2022","unstructured":"Al Dahmani KM, Almalki MH, Ekhzaimy A, Aziz F, Bashier A, Mahzari MM et al (2022) Proportion and predictors of hypogonadism recovery in men with macroprolactinomas treated with dopamine agonists. Pituitary 25(4):658\u2013666. https:\/\/doi.org\/10.1007\/s11102-022-01242-y","journal-title":"Pituitary"},{"issue":"6","key":"1548_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","volume":"25","author":"Y Rudman","year":"2022","unstructured":"Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I (2022) Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6):882\u2013890. https:\/\/doi.org\/10.1007\/s11102-022-01259-3","journal-title":"Pituitary"},{"issue":"2","key":"1548_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1210\/jc.2003-030852","volume":"89","author":"M De Rosa","year":"2004","unstructured":"De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova L et al (2004) Six months of treatment with Cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89(2):621\u2013625. https:\/\/doi.org\/10.1210\/jc.2003-030852","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1548_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/a:1025377816769","volume":"5","author":"L Sibal","year":"2002","unstructured":"Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH et al (2002) Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5(4):243\u2013246. https:\/\/doi.org\/10.1023\/a:1025377816769","journal-title":"Pituitary"},{"key":"1548_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04215-w","author":"Y Rudman","year":"2025","unstructured":"Rudman Y, Simon N, Shimon R, Drozdinsky G, Markus E, Duskin-Bitan H et al (2025) Response to Cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study. Endocrine. https:\/\/doi.org\/10.1007\/s12020-025-04215-w","journal-title":"Endocrine"},{"issue":"2","key":"1548_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.17925\/EE.2019.15.2.83","volume":"15","author":"CJ Fernandez","year":"2019","unstructured":"Fernandez CJ, Chacko EC, Pappachan JM (2019) Male Obesity-related secondary Hypogonadism - Pathophysiology, clinical implications and management. Eur Endocrinol 15(2):83\u201390. https:\/\/doi.org\/10.17925\/EE.2019.15.2.83","journal-title":"Eur Endocrinol"},{"issue":"6","key":"1548_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1530\/EJE-12-0955","volume":"168","author":"G Corona","year":"2013","unstructured":"Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M et al (2013) Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 168(6):829\u2013843. https:\/\/doi.org\/10.1530\/EJE-12-0955","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1548_CR31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/andr.12774","volume":"8","author":"A Barbonetti","year":"2020","unstructured":"Barbonetti A, D\u2019Andrea S, Francavilla S (2020) Testosterone replacement therapy. Andrology 8(6):1551\u20131566. https:\/\/doi.org\/10.1111\/andr.12774","journal-title":"Andrology"},{"key":"1548_CR32","doi-asserted-by":"publisher","first-page":"1201313","DOI":"10.3389\/fendo.2023.1201313","volume":"14","author":"EV Munari","year":"2023","unstructured":"Munari EV, Amer M, Amodeo A, Bollino R, Federici S, Goggi G et al (2023) The complications of male hypogonadism: is it just a matter of low testosterone? Front Endocrinol (Lausanne) 14:1201313. https:\/\/doi.org\/10.3389\/fendo.2023.1201313","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1548_CR33","doi-asserted-by":"publisher","first-page":"2271514","DOI":"10.1155\/2021\/2271514","volume":"2021","author":"M Vakhshoori","year":"2021","unstructured":"Vakhshoori M, Heidarpour M, Bondariyan N, Sadeghpour N, Mousavi Z (2021) Adrenal insufficiency in coronavirus disease 2019 (COVID-19)-Infected patients without preexisting adrenal diseases: A systematic literature review. Int J Endocrinol 2021:2271514. https:\/\/doi.org\/10.1155\/2021\/2271514","journal-title":"Int J Endocrinol"},{"key":"1548_CR34","doi-asserted-by":"publisher","unstructured":"Jensterle M, Herman R, Janez A, Mahmeed WA, Al-Rasadi K, Al-Alawi K et al (2022) The relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal axis: A large spectrum from glucocorticoid insufficiency to excess-the CAPISCO international expert panel. Int J Mol Sci 23(13). https:\/\/doi.org\/10.3390\/ijms23137326","DOI":"10.3390\/ijms23137326"},{"issue":"1","key":"1548_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12020-024-03705-7","volume":"85","author":"R Cannarella","year":"2024","unstructured":"Cannarella R, Marino M, Crafa A, Bagnara V, La Vignera S, Condorelli RA et al (2024) Impact of COVID-19 on testicular function: a systematic review and meta-analysis. Endocrine 85(1):44\u201366. https:\/\/doi.org\/10.1007\/s12020-024-03705-7","journal-title":"Endocrine"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01548-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T03:58:49Z","timestamp":1756267129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01548-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01548-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]},"assertion":[{"value":"6 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.F. has received lecture, advisory board, and steering committee fees as well as research grants from Recordati Rare Diseases, Camurus, Novartis-Advanced Accelerator Applications, Ipsen, and Bristol-Myers Squibb. F.G. has received lecture\/manuscript writing and advisory board fees from Recordati Rare Diseases, Camurus, Ipsen, and Pfizer; F.G. is Associate Editor of Pituitary. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}